Background: Grip strength and 2 minute walk test have been suggested as elements of chronic graft-vs-host disease (GVHD) assessment in clinical trials. Methods: Using all available data (n¼584, 1,689 follow-up visits, total of 2,273 visits) from a prospective observational cohort study, we explored the relationship between grip strength and 2 minute walk test and patient-reported outcomes (Lee symptom scale, SF-36 and FACT-BMT quality of life instruments, and Human Activity Profile, or HAP), chronic GVHD severity (NIH global 0-3 score, clinician global 0-3 score, and patient-reported global 0-3 score) and mortality (overall survival (OS) and non-relapse mortality (NRM)) in multivariate analyses adjusted for significant covariates. Results: In multivariate analysis, 2 minute walk test was significantly ( P < .001) associated with intuitive domains of the Lee Symptom Scale (overall, skin, lung, energy), while grip strength was not. Excepting MCS (mental component score), 2 minute walk test had significant association with all studied SF-36 domain and summary scores ( P < .001) and FACT summary and domain scores ( P < .001). Both grip strength and 2 minute walk test had significant association with FACT summary scores and HAP (maximum activity score (MAS), and adjusted activity score (AAS)). In univariate analysis using all visit data, 2 minute walk test had significant association with global chronic GVHD severity, as calculated from organ scores, reported by clinicians, and reported by patients ( P < .01). Patients with NIH global score of mild or less and moderate achieved on average 20.7 and 15.3 feet, respectively, greater distance covered compared to those with NIH severe chronic GVHD. Conversely, grip strength had no significant association with any of these measures of chronic GVHD. In time-varying multivariate models examining all data and adjusting for significant covariates, 2 minute walk test was significantly associated with both OS and NRM (both P < .001), while no association was found for grip strength.
Conclusions: Based on its consistent association with symptom burden, QOL, chronic GVHD severity and mortality, these data support the 2 minute walk test as a useful measure in chronic GVHD assessment. , 14, 21, 30, 45, 60, 100, 180, and 365 relative to HSCT for tryptophan (Trp) and kynurenine (Kyn) quantification (mM) by high performance liquid chromatography. Mann-Whitney rank tests were used to test associations between Kyn/Trp ratio (IDO activity) and area under the curve (AUC) Kyn/Trp ratio and GVHD. Potential confounders were tested for association with GVHD using Fisher's exact tests (#) or Mann-Whitney rank tests ( * ). Analyses were performed using R (ver 2.12.1) and GraphPad Prism (ver 5.04). Results: Twenty patients were evaluable for IDO activity and GVHD. AML was the most common diagnosis (n ¼ 9, 45%). All patients engrafted at mean (SD) 17.2 (+/-5) days. Acute GVHD occurred in 13 (59.1%) patients: 10 were Grade I-II and 3 were Grade III. Median time to GVHD diagnosis was 46 days. 
